Geron
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
919 E Hillsdale Blvd Ste 250, Foster Cit...Phone Number
(650) 473-7700Website
www.geron.comRevenue
$204.6 MillionStock Symbol
GERNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Geron
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.Explore more
Geron Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Geron your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Geron launches new products
Check out if Geron is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Geron, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Geron recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Geron
Website visits: Recent activity has been detected on your website
Click to see if Geron had a recent Job posting/layoffs
Check if Geron has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Geron has new funding data
Recommended Actions
Reach out to Masked Content who joined Geron as Masked Content
Find more new buyers
Compare Similar Companies to Geron
Compare insights from companies similar to Geron, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Geron
$204.6M
201-500
Public
$466M
1990
MR
Michelle RobertsonExecutive Vice President & Chief Financial Officer & Treasurer
Company Profile Activity
Activity Insights
Geron is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Geron is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Geron.
Geron financials insights
Gather financial insights about Geron, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
1996
Stock Offering
$16M
2020
Debt
$75M
2024
Debt
$375M
Geron Tech Stack
A closer look at the technologies used by Geron
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Earnings, Finance, Revenue Operations
Person-Based
Earnings, Finance
Earnings
reported total operating expenses, excluding cost of goods sold, of $60.7 million for Q2 2026 ended June 30, 2026, compared to $60.3 million for the same period in 2025, with continued investments in commercial strategy and CMC partially offset by lower headcount costs from the December 2025 workforce reduction.
Earnings, Spending/Investment, Finance
Earnings
Earnings, Finance
Geron News & Media
Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands
Geron (NASDAQ:GERN) executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results toward the midpoint to high end of that range, or approximately $230 million to $Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands
Geron (NASDAQ:GERN) said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS. DurDid Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders should contact the...Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Geron Corporation (NASDAQ: GERN) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Geron...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Geron
Sign Up For FreeTo access detailed company insights
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosi... Read More
